The study included 134 patients who underwent two cycles of controlled ovarian stimulation (COS) with an antagonistic protocol; 66 patients became infected with COVID‑19 between the first and second cycles, and 68 remained uninfected. Baseline characteristics, ovarian reserve profiles, and responses to stimulation did not differ between infected and uninfected groups. In the uninfected group, the rate of available and high-quality embryos improved significantly in the second cycle. In the infected group, a higher rate of blastocyst formation was observed after COVID‑19 (p = 0.011), but the rate of high-quality embryos was not significantly different between pre- and post-infection cycles. After stratifying the infected group according to the interval from infection to oocyte collection, an increase in the number of both total and high-quality blastocysts was observed in the 181–240 days post-infection subgroup. Pregnancy outcomes were similar between infected and uninfected patients. The authors conclude that although COVID‑19 may have abrogated the benefit of improvement with a repeat cycle, no deleterious effects on laboratory or clinical outcomes or ovarian function were observed.